SCHEMBL661999

SCHEMBL661999

CCCCCB(O)OC(C)(C)C(C)(C)O

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17891917 0.98 ANPEP (0.33) ANPEP
SCHEMBL5953079 0.94 ANPEP (0.41) ANPEP
SCHEMBL9903702 0.80
SCHEMBL1300947 0.80
SCHEMBL290668 0.76 ALDH1A1 (0.31)
SCHEMBL17652427 0.74 FAAH (0.38)
SCHEMBL3709629 0.73
SCHEMBL1726025 0.71 ANPEP (0.46) ANPEP
SCHEMBL10624549 0.70
SCHEMBL18074209 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115490715-A Method for preparing aryl boronic acid pinacol ester compound by taking phenol as raw material 遵义医科大学 2022-12-20 CN claimed
CN-115286553-A Preparation method of indole compound 浙江理工大学 2022-11-04 CN claimed
CN-113956185-A Method for efficiently preparing aromatic urea compound 常州大学 2022-01-21 CN claimed
CN-109896977-B Synthetic method of biaryl phenol ester 吉林大学 2021-09-28 CN claimed
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 US disclosed
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 US disclosed
WO-2024145273-A2 N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) 2024-07-04 WO disclosed
WO-2024118960-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. (US) 2024-06-06 WO disclosed
WO-2024118966-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. (US) 2024-06-06 WO disclosed
EP-4359395-A1 HERBICIDAL ARYLCYCLOPENTENE CARBOXAMIDES BASF SE (DE) 2024-05-01 EP disclosed
EP-4359396-A1 HERBICIDAL ARYLDIHYDROFURANE CARBOXYLATES BASF SE (DE) 2024-05-01 EP disclosed
US-11945830-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2024-04-02 US disclosed
EP-2592154-A1 Immobilization products and methods for the identification of histone demethylase interacting molecules and for the purification of histone demethylase proteins CELLZOME AG (DE) 2013-05-15 EP disclosed
US-8288604-B2 Method of rapid methylation, kit for preparing PET tracer and method of producing PET tracer GIFU UNIVERSITY (JP) 2012-10-16 US disclosed
WO-2012052390-A1 N-2-(2-PYRIDINYL)-4-PYRIMIDINYL-BETA-ALANINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE JMJD3 GLAXO GROUP LIMITED (GB) 2012-04-26 WO disclosed
US-20120046278-A1 THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2012-02-23 US disclosed
EP-2405973-A2 THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-01-18 EP disclosed
US-20100249477-A1 Method of Rapid Methylation, Kit for Preparing PET Tracer and Method of Producing PET Tracer GIFU UNIVERSITY (JP) 2010-09-30 US disclosed
WO-2010103130-A2 NOVEL BICYCLIC HETEROCYCLES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-09-16 WO disclosed
EP-2070897-A1 METHOD OF RAPID METHYLATION, KIT FOR PREPARING PET TRACER AND METHOD OF PRODUCING PET TRACER Gifu University (JP) 2009-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216516-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF KRAS, VHL, HRAS ANPEP 3073/4885
US-20100249477-A1 Method of Rapid Methylation, Kit for Preparing PET Tracer and Method of Producing PET Tracer DNMT1, MAP2K1, DOT1L ANPEP 1376/4885
US-20120046278-A1 THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS TPMT, STAT6, IL4 ANPEP 4420/4885
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF KRAS, VHL, HRAS ANPEP 2863/4885
US-11945830-B2 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 ANPEP 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.